Kangstem Biotech Co., Ltd. (KOSDAQ:217730)

Market Cap	117.15B
Revenue (ttm)	12.77B
Net Income (ttm)	-8.28B
Shares Out	56.05M
EPS (ttm)	-152.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	626,826
Average Volume	319,099
Open	2,200.00
Previous Close	2,165.00
Day's Range	2,060.00 - 2,245.00
52-Week Range	1,388.00 - 3,920.00
Beta	0.16
RSI	49.44
Earnings Date	Mar 14, 2025

About Kangstem Biotech

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 97
• Stock Exchange: KOSDAQ
• Ticker Symbol: 217730

Financial Performance

In 2023, Kangstem Biotech's revenue was 12.70 billion, a decrease of -22.06% compared to the previous year's 16.30 billion. Losses were -21.95 billion, 8.47% more than in 2022.